Redx Pharma Plc (LON:REDX) Insider Buys £31,920 in Stock

Redx Pharma Plc (LON:REDX) insider Lisa Anson purchased 399,000 shares of the company’s stock in a transaction dated Thursday, April 11th. The stock was purchased at an average price of GBX 8 ($0.10) per share, with a total value of £31,920 ($40,399.95).

Redx Pharma Stock Up 5.3 %

REDX opened at GBX 7.90 ($0.10) on Monday. The company has a quick ratio of 1.93, a current ratio of 1.11 and a debt-to-equity ratio of 527.00. The firm has a market cap of £30.73 million, a P/E ratio of -82.50 and a beta of -0.53. Redx Pharma Plc has a 52 week low of GBX 4 ($0.05) and a 52 week high of GBX 37.90 ($0.48). The business’s fifty day simple moving average is GBX 17.42 and its 200 day simple moving average is GBX 21.41.

Redx Pharma Company Profile

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.